Putting criticism about timing and data presentation aside, $ERAS' ERAS-0015 seems very similar to $RVMD's daraxonrasib imo.
ERAS-0015 is more potent which explains the lower exposure required for efficacy (and associated with on target toxicity of course). It might have a slight advantage on GI side effects (to be seen) but other than that it is likely to have a similar therapeutic index.
If we compare just the PDAC data sets, $ERAS reported 4 PRs in 21 patients (~19% ORR) in the US at relevant doses which is lower than dara's 35% ORR but that gap will likely close with more follow up as $ERAS has multiple near PRs at the first scan than can convert in the future (They need 3 such conversions to reach 33% ORR).
The limited follow up probably has a confounding effect on safety as well (longer treatment typically leads to more side effects) which should take $ERAS to a similar dose interruption/reduction rate in the future. Gr5 pneumonitis case requires attention but it could be an isolated case.
Is $ERAS cheap at $3B? Not sure but for pharmas who cannot afford or simply won't get $RVMD this is the closest fast follower program that could be P3 ready later this year.
*no position in stocks mentioned *
@JoseRestonVA@Investorclimber $ABVX 2/2 Other red flags for me were the comments about fierce competition in the space, repeatedly saying “we need more data,” etc.
Don’t get me wrong I like $ABVX and I think it will get approved. But the CC was a cold shower for all those relentless rosy projections here on X
@AppleHelix It was originally backed by Petr Kellner, at the time the wealthiest Czech, to develop the dendritic cell cancer vaccine DCVAC. It later pivoted toward in-licensing oncology assets, mainly ADCs. After Kellner died in 2021, SOTIO has continued to be backed by the Kellner family.
@Banana_Oncology See Enzalutamide and Apalutamide. See a lot of similarities here. There’s a lane where $eras could succeed, likely in hands of larger company w resources.
@CloisterRes@ScroogeCap What’s the core long thesis on $BNTX? Is it that PD-L1/VEGF will prove better than $SMMT’s PD-1/VEGF, or is this mostly a bet on a favorable COVID vaccine settlement headline, especially after the Moderna precedent?
@RNAiAnalyst Congratulations, Dirk - you’ve been on an absolute tear this year! I admire your strong conviction and your willingness to go against the crowd!
Join @adamfeuerstein, Biotech Hangout, and the BioX community for a special memorial on Tuesday, Dec. 16 at 5 PM EST. Biotech Hangout will host an X Space to honor and celebrate the lives of Michelle “Molly” Solly (@MSollender) and Hudson Lau (@Sports_Bios).
This will be an open space for the community to share memories and stories. Please save the date for this special event – link coming soon.
@avidresearch IF HOPE3 is +ve w/ LVEF - mktcap for $CAPR will be 5X or higher from here - ..and on DMD alone - .. I can not stress enough the accommodations the FDA has done for DMD applications, and the evolving CBER for orphan diseases under Peter Marks.